Phase 2 Depression and Anxiety Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Adults aged 18 or older
- People who are able to give informed consent to participate
- People who can understand written and spoken Portuguese
- People who are willing to have blood samples taken
- People who are willing to avoid intense physical exercise for 72 hours before their assessment
- People who have been diagnosed with depression (according to specific diagnostic standards called DSM-5/MINI) that has not responded to at least two adequate courses of treatment
- People who score 19 or higher on a standard depression rating scale (called the HDRS) at the start of the trial
- People who have a blood inflammation marker called CRP at a level of 3 mg/L or higher
For the 10 healthy volunteers being recruited separately for comparison purposes:
- Adults aged 18 or older
- People with no current or past psychiatric diagnosis, as measured by a screening tool called the SRQ-20
- People who are able to give informed consent
- People who can understand written and spoken Portuguese
- People who are willing to have blood samples taken
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have a diagnosis of bipolar disorder or a personality disorder
- People who have had a substance use disorder in the past six months
- People who have an active or recent infection (including tuberculosis, Hepatitis B, Hepatitis C, or HIV) or an autoimmune disease
- People who are pregnant or breastfeeding
- People who have a history of significant heart disease, recent cancer, or blood disorders
- People with a BMI over 40 kg/m² or who weigh more than 100 kg
- People who have a known allergy or sensitivity to the study drug (tocilizumab) or any of its ingredients
- People whose CRP blood inflammation level is 20 mg/L or higher
- People with active liver disease or elevated liver enzymes above a certain threshold (more than 1.5 times the upper limit of normal)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Neusa Sica da Rocha, PhD, Federal University of Rio Grande do Sul (UFRGS)
Phone: 55(51) 3359-8000
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Reduction in depressive symptoms (HDRS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.